Amersham Health

Amersham Health was a premier global provider of diagnostic imaging agents and radiopharmaceuticals, specializing in products for X-ray, MRI, and nuclear medicine. The company's portfolio included industry-standard contrast media such as Omnipaque and Visipaque, as well as innovative molecular imaging probes like DaTSCAN for Parkinson's disease. Formed from the merger of Amersham International and Nycomed, the company played a pivotal role in advancing medical diagnostics across oncology, cardiology, and neurology. In 2004, Amersham plc was acquired by General Electric for approximately $9.5 billion. This acquisition integrated Amersham Health into GE Healthcare, significantly expanding GE's capabilities in personalized medicine and diagnostic technology.